Back to top

vaccines: Archive

Zacks Equity Research

Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids

Pfizer (PFE) and partner BioNTech seek authorization from the FDA for using their bivalent COVID-19 booster vaccine in kids. The vaccine is already authorized for use in adolescents and adults.

PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change

Zacks Equity Research

Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why

Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

AZNPositive Net Change PFENegative Net Change VALNNegative Net Change

Zacks Equity Research

Why Novavax (NVAX) Stock Was Down 13% on Thursday

Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Kinjel Shah

Vaccine Stocks Down After Biden Says Pandemic is Over

BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Merck's (MRK) Pneumococcal Jab Gets CHMP Endorsement for Kids

The EMA's CHMP recommends approving Merck's (MRK) pneumococcal 15-valent conjugate vaccine for expanded use in infants and children. The vaccine received similar approval from the FDA in June 2022.

PFENegative Net Change MRKPositive Net Change KMDANegative Net Change

Zacks Equity Research

Pfizer's (PFE) Late-Stage Meningococcal Jab Study Meets Goal

Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.

GSKPositive Net Change PFENegative Net Change KMDANegative Net Change

Derek Lewis

3 Mega-Cap Stocks With Unbelievably Strong Free Cash Flow

All three companies generate substantial cash. In fact, one reported the highest quarterly free cash flow of any S&P 500 company in Q2.

AAPLPositive Net Change PFENegative Net Change GOOGLNegative Net Change

Zacks Equity Research

Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine

Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.

PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change

Zacks Equity Research

Pfizer (PFE), BioNTech Omicron BA.4, BA.5 Boosters Get CHMP Nod

Pfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.

PFENegative Net Change MRNANegative Net Change AGENPositive Net Change BNTXNegative Net Change

Zacks Equity Research

Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults

Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate

Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.

MRKPositive Net Change EBSNegative Net Change INOPositive Net Change PLRXPositive Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights Pfizer /BioNTec and Moderna's

Pfizer /BioNTec and Moderna are part of The Zacks top Analyst Blog.

PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change

Kinjel Shah

FDA Authorizes Pfizer, Moderna's Omicron-Based Boosters

Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) develop the Omicron BA.4/BA.5-adapted bivalent vaccines at the FDA's recommendation.

PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change